Kornimate/medical-research-clean huggingface dataset:
a prospective multi-center study on using sonazoid diagnose early stage endometrial cancer

Conditions: Endometrial Carcinoma Stage I

Summary: sonazoid as a new generation of ultrasound contrast agent.this study based on the features of sonazoid specific angiography and higher mechanical index, the role of sonazoid in the early diagnosis of endometrial carcinoma was explored.

sonazoid is a second generation ultrasound contrast agent, which is composed of microbubbles containing chemically stable and insoluble perfluorobutane (pfb) gas and a hard shell of phosphatidylserine sodium (2-3 μ m in diameter) wrapped in the outer layer. these microbubbles can generate stable nonlinear oscillations in a low-power acoustic field and generate echoes at the second harmonic frequency of the transmitted pulse for enhanced contrast harmonic imaging. because sonazoid has the advantages of ultra long time development and good stability, sonazoid has significant clinical advantages in the diagnosis of not focal liver lesions(flls) but breast tumor and other organ. however, there is no study based on contrast enhanced ultrasound(ceus) using sonazoid in early detection of endometrial carcinoma. therefore, based on the advantages of the new ultrasound contrast agent, using qualitative analysis and quantitative analysis method to collect large samples, compared with diagnosis results of standard reference, which has important clinical significance for early diagnosis, early detection and improving the accuracy of diagnosis of endometrial carcinoma.

Eligibility criteria:
inclusion criteria: * 1)patients with irregular vaginal bleeding with endometrial thickness is greater than 5mm(postmenopausal) or10mm (premenopausal) via transvaginal ultrasound； * 2)able to perform curettage or other image examination and surgical pathological staging； * 3) patients with complete clinical data, pathological test and follow-up data； * 4)ability to understand, sign informed consent and agree to participate in the investigator. exclusion criteria: * 1)patients without endometrial carcinoma; * 2)women during pregnancy and lactation; * 3)those who are known to be allergic to ultrasound contrast agents; * 4)patients with arterial-venous (right to left) shunt in the heart or lung or with serious heart diseases or with serious lung diseases; * 5)any other condition makes patient not eligible for this clinical trial.

Keywords: contrast enhanced ultrasound transvaginal ultrasound
sentinel lymph node biopsy findings in patients with breast cancer

Conditions: Breast Cancer

Summary: to compare the kinetics and efficacy of two functionally different diagnostic agents, lymphoseek (cd206 receptor targeted) and 99mtc-sulfur colloid (sc) (sulfur colloid non-specific mapping agent) in intraoperative lymphatic mapping (ilm) and sentinel lymph node biopsy (slnb).

single center, blinded, randomized, parallel-group, comparative study of lymphoseek and 99mtc-sc in the preoperative and intraoperative detection of lymph nodes in subjects with known breast cancer. all subjects will receive a single dose of 50 μg lymphoseek radiolabeled with 0.5 millicurie (mci) tc 99m or 0.5 mci of 99mtc-sc. subjects may also receive up to 1 ml of vital blue dye (vbd) as a companion ilm agent. all radio-labeled agents will be administered in a single intradermal injection.

Eligibility criteria:
inclusion criteria: * the subject must be female and 18 years of age or older. * the subject must be a preoperative clinical tis, t1, t2, t3, t4, as well as clinical n0 and clinical m0 breast cancer * the subject must have a diagnosis of primary breast cancer. * the subject must be a candidate for surgical intervention, either with lumpectomy and slnb or with mastectomy and slnb, as the treatment of her breast cancer. * the subject must have an eastern cooperative oncology group (ecog) performance status of grade 0 - 2 * the subject must provide written informed consent with health insurance portability and accountability act (hipaa) authorization before participating in the study exclusion criteria: * the subject has clinical or radiological or pathologic evidence of metastatic cancer, including any abnormal or enlarged clinical palpable lymph nodes or core biopsy/surgical biopsy/fine-needle-aspiration evidence of malignant cell within any lymph nodes. * the subject has a known hypersensitivity to vital blue dye (vbd) in a case where vital blue dye was planned for use during slnb. * the subject has a positive pregnancy test or is lactating. * the subject has had prior surgery to the indicated breast or axilla.

Keywords: sentinel node
primary mesh closure of abdominal midline wounds

Conditions: Incisional Hernia Occurence

Summary: incisional hernia is the most frequently seen long term complication in surgery causing much morbidity and even mortality in patients. despite studies on the optimal closing technique for laparotomies, the risk for incisional hernia after midline incision remains about 5-20 %. major risk factors for incisional hernia after a laparotomy, like obesity, steroid use, malnutrition, smoking and connective tissue disorders, are known. despite this knowledge, there has not yet been developed a sufficient method for prevention. one specific group of high risk patients are patients with an abdominal aortic aneurysm (aaa). the relationship between aortic aneurysm and other abdominal wall hernias, like inguinal hernias, has been reported. retrospective and prospective studies have shown an average risk for incisional hernia after aaa repair of 31.6 %. another high risk group is the group of obese patients. patients with a bmi of more than 27 have a high risk of developing an incisional hernia after midline incision with an incidence of 22% after 12 months. considering only 50 % of incisional hernia will be clinically evident in the first 12 months, the total incidence will be above 30%. this high risk group of patients with obesitas and aneurysmatic disease can benefit most from prevention. some small studies have been performed to evaluate the usefulness and safety of primary laparotomy wound closure with the aid of prosthetic mesh. these studies show a very low risk for incisional hernias and a low infection rate, even when used in contaminated wounds such as colostomal surgery. however, there has not been performed an adequate randomized controlled trial to study the prevention of incisional hernias. our hypothesis is that incisional hernia prevention with use of prosthetic mesh after laparotomy is effective in patients with aortic aneurysm and in obese patients with a bmi of more than 27.


Eligibility criteria:
inclusion criteria: * every elective midline laparotomy for patients with abdominal aortic aneurysm and patients with a bmi of more than 27. * signed informed consent exclusion criteria: * age \< 18 years * emergency procedure * inclusion in other trials * aortic reconstruction for obstructive disease * life expectancy less than 24 months * pregnant women

Keywords: incisional hernia
stem cell translpantation in multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to determine whether autologous transplantation (using the patient's own stem cells from the blood), followed by non-myeloablative (i.e. less intense) allogeneic transplantation (where the blood stem cells from a sibling donor are used for the transplantation) improves the outcome in patients with newly diagnosed multiple myeloma.

this trial includes a natural (no available hla-identical sibling donor) control arm. patients with newly diagnosed multiple myeloma without a sibling are initially treated with conventional chemotherapy followed by conventional single or double autologous transplant (pbsct). data from this group is used as part of the control group. eligible patients with one or more sibling are offered to participate in the main trial arm. those who decline are asked to consider taking part in the control group (autograft only). patients consenting to participate in the main study first receive the pbsct, followed by the hla-matched non-myeloablative allograft (matched for hla -a, -b, -c, -drb1). all study patients receive four to six cycles of vad (or alternative regimens specified in protocol) before pbsct as first line treatment. study entry starts at the time of starting conditioning for autologous transplantation. the search for an identical sibling donor begins as soon as the patient has consented to participate in the study. the allograft is performed when the patient has restored their marrow function but no earlier than 3 months following pbsct. the aim is to demonstrate a difference in outcome (progression free survival, transplant related mortality, relapse rate, and survival).

Eligibility criteria:
inclusion criteria: * newly diagnosed stage-ii and iii multiple myeloma (according to durie and salmon classification) * age under 70 years * life expectancy over 3 months * patients must be able to give informed consent exclusion criteria: * serious concomitant medical disease which would limit life span or the ability to tolerate chemotherapy * severe cardiac failure (ejection fraction \<40%) * impairment of renal function at diagnosis is not per se reason for exclusion but patients with severe impaired renal function (gfr \<50 ml/min) after initial vad (or vad like) induction treatment are excluded * severe impairment of liver function (bilirubin \>2 times upper limit of normal) * pregnant or lactating women * other major organ system dysfunction (gi, neurological, psychiatric dysfunction) that impairs tolerance of therapy or prolong hematological recovery

Keywords: myeloma hla-matched autologous allogeneic transplant
observational study of the genetic architecture of neutrophil-mediated inflammatory skin diseases

Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue; Pyoderma Gangrenosum; Erosive Pustular Dermatosis of the Scalp; Sweet's Syndrome; Behcet's Disease; Bowel-associated Dermatosis-arthritis Syndrome; Pustular Psoriasis; Acute Generalized Exanthematous Pustulosis; Keratoderma Blenorrhagicum; Sneddon-Wilkinson Disease; IgA Pemphigus; Amicrobial Pustulosis of the Folds; Infantile Acropustulosis; Transient Neonatal Pustulosis; Neutrophilic Eccrine Hidradenitis; Rheumatoid Neutrophilic Dermatitis; Neutrophilic Urticaria; Still's Disease; Erythema Marginatum; Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes; Dermatitis Herpetiformis; Linear IgA Bullous Dermatosis; Bullous Systemic Lupus Erythematosus; Inflammatory Epidermolysis Bullosa Aquisita; Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis); Small Vessel Vasculitis Including Urticarial Vasculitis; Erythema Elevatum Diutinum; Medium Vessel Vasculitis

Summary: this study investigates the genetic architecture of neutrophil-mediated inflammatory skin diseases. after collecting informed consent, all patients' clinical phenotype is graded at inclusion with a detailed case report form and a discovery cohort formed based on the certainty of diagnosis. the dna of patients in the discovery cohort is analyzed by whole exome sequencing which identifies all protein-coding genetic variants. subsequently, statistical burden tests are going to identify enrichment of rare coding genetic variants in patients affected by neutrophil-mediated inflammatory skin diseases. the ultimate goal is to reveal the responsible gene(s) that may then be targets for clinical intervention.

timeframe: * collection of dna for discovery cohort until 05/2016 * data analysis until 12/2014 for pyoderma gangrenosum, until 12/2016 for other nmid * report and data presentation early 2015 for pg, 2017 for other nmid

Eligibility criteria:
inclusion criteria: * history of nmid or active disease. * informed consent. exclusion criteria: - no consent to either part of the study.
effects of hemiplegic shoulder pain

Conditions: Stroke; Shoulder Pain

Summary: the purposes of this study is to investigate the differences in upper extremity function, sleep quality, and functional independence between patients with and without hemiplegic shoulder pain (hsp). hsp is defined as musculoskeletal pain in the affected shoulders of individuals after stroke.numerous studies have found an association between post-stroke shoulder pain and range of motion, sensory impairment, subluxation, spasticity, and complex regional pain syndrome. hsp is a problem that, starting from mild discomfort, leads to gradual functional impairment, ultimately resulting in increasing disability and decreased independence.in the literature, the relationship between hsp and upper extremity function, functional independence, and sleep quality has not been clarified.


Eligibility criteria:
inclusion criteria: * over 18 years old * have had a stroke at least three months ago * volunteers who can understand or communicate test instructions exclusion criteria: * having a history of shoulder surgery * having serious shoulder problems before stroke * having other neurological conditions
cyanoacrylate with sutures for fixation of free gingival graft

Conditions: Soft Tissue Atrophy

Summary: fixation of fgg with sutures alone is not sufficient,we use cyanoacrylate beside sutures for fixation

inadequate zone of attached mucosa around implants, gingival recession, inadequate ridge width or height despite there is enouph bone for implant placement are problems that face periodontists and can be treated by soft tissue graft studies have demonstrated the importance of the tissues stability for the first hours when support is provided by underlying osseous or dental structures. movement of the graft during mastication and phonation will disturb healing procedures. most of the clinicians prefer a protective device during the healing phase. transitional dentures are not stable themselves, and hence are not suitable for stabilizing. circummandibular wiring and impact posts are seemingly very aggressive for patients and need extra clinical practices, skills, and equipment. studies proved that the maximum tissue shrinkage (approximately 20%-40%) occurs during the first 3 months post operation and will proceed until 12 postsurgical months with a persistent, significantly lower rate. in this study we give more stabilization for free gingival grafts by using cyanoacrylate tissue adhesive beside sutures its autogenous character, maintenance of keratinization, predictability, ease of technique tlead ctg to be accepted as the golden standard to increase attached gingival dimensions cyanoacrylate is a simple, inexpensive haemostatic and biocompatible material it is used as tissue adhesives in paediatric surgery general surgery and also dentistry. it has been applied intraorally with different purposes such as periodontal dressing,for sealing sinus membrane perforations for stabilizing bone fragments during fracture fixation, and in closing peripheral nerve anastomosis it seems promising in the intraoral field due to their strong sealing, bacteriostatic, and hemostatic properties. multiple studies examined the use of cyanoacrylate glues as an alternative to suturing intraoral and extraoral wounds concluding that cyanoacrylates are faster, more reliable ,and less painful and cause better hemostasis .

Eligibility criteria:
inclusion criteria: * patients with hopeless teeth that need extraction * age: between 20 and 60 years * both sexes. * subjects willing to sign an informed consent form ,participate in the study and return for follow-up visits exclusion criteria: * • patients with coagulation disorders (hemophilia a/b, von willebrand disease, liver disease, anticoagulative therapy), * patients on corticosteroids, * patients with uncontrolled diabetes mellitus * smokers * pregnant or lactating mother. * known systemic diseases and/ or drug therapy which may interfere with wound healing or contraindicate periodontal therapy * allergy to cyanoacrylate
safety and immunogenicity of gsk bio's candidate hbv-mpl vaccines compared to engerix™-b, in healthy adolescents

Conditions: Hepatitis B

Summary: in this study the safety and immunogenicity of 2 different formulations of the candidate hbv-mpl vaccine administered according to a 0, 6-month schedule were explored and compared to that of engerix™-b in healthy adolescents aged 11 to 15

at the time of conduct of this study, the sponsor glaxosmithkline was known by its former name smithkline beecham

Eligibility criteria:
inclusion criteria: * age: between 11 and 15 years at the time of the first vaccination. * free of obvious health problems as established by medical history and clinical examination before entering into the study. * written informed consent obtained from the parents or guardians of the subject and from the subject himself/herself in all subjects 15 years of age. * if the subject is female, she must be of non-childbearing potential, if of childbearing potential, she must be abstinent or have used an adequate contraceptive for one month prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series exclusion criteria: * use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine. * administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within six months of vaccination. * planned administration of a vaccine not foreseen by the study protocol during the period starting from one week before each dose of vaccine and ending 30 days after. * previous vaccination against hepatitis b virus. * previous vaccination with vaccine containing mpl. * any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection. * history of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * acute disease at the time of enrollment. * hepatomegaly, right upper quadrant abdominal pain or tenderness. * axillary temperature of ≥ 37.5° c. * administration of immunoglobulin and / or any blood product within the six months preceding the first dose of study vaccine or planned administration during the study period. * pregnant or lactating female. * history of chronic disease deemed by the investigator to be relevant. * positive for anti-hbv antibodies at screening

Keywords: hepatitis b recombinant hepatitis b vaccine adjuvant
15-year mortality after hospitalization for exacerbation of chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease; Exacerbation Copd; Mortality

Summary: the investigators examine the 15-year mortality after an admission for an exacerbation of chronic obstructive pulmonary disease (copd).

several prognostic factors will be examined. cause of death will be examined. data will be recruited from medical records and calling general practitioners to find out if a patient is still alive. statistical analysis will be done with kaplan meier, cox proportional hazards and chi square

Eligibility criteria:
inclusion criteria: * admission with exacerbation of copd exclusion criteria: * none
a study to evaluate the safety and immune responses to fluzone® vaccination

Conditions: Influenza

Summary: to describe the safety of the inactivated, split-virion influenza vaccine, 2008-2009 formulation. to evaluate the compliance, in terms of immunogenicity, of the inactivated, split-virion influenza vaccine 2008-2009 formulation with the requirements of the committee for human medicinal products (chmp) note for guidance (nfg) cpmp/bwp/214/96.


Eligibility criteria:
inclusion criteria: * participant is 18 years of age or older on the day of inclusion. * participant willing and able to attend scheduled visits and to comply with the study procedures during the entire duration of the study. * participant in reasonably good health as assessed by the investigator. * participant willing and able to give informed consent. * for a woman, inability to bear a child or negative serum/urine pregnancy test. exclusion criteria: * self-reported allergy to egg proteins, chicken proteins, or one of the constituents of the vaccine, such as thimerosal or formaldehyde. * an acute illness with or without fever in the 72 hours preceding enrollment in the trial. * clinically significant findings in vital signs (including temperature ≥ 99.5°f oral) or review of systems. * self-reported history of severe adverse event to any influenza vaccine. * laboratory-confirmed influenza infection or vaccination against influenza in the 6 months preceding enrollment in the study. * any vaccination in the 14 days preceding enrollment in the study or scheduled between visit 1 and visit 2. * participation in any other interventional drug or vaccine trial within the 30 days preceding or during enrollment into this study.\* * immunocompromising condition or immunosuppressive therapy (including systemic steroid use for 2 weeks or more), cancer chemotherapy, or radiation therapy at the time of enrollment, planned during the period of this study, or at any time within the past 6 months. * receipt of blood or blood products within the 3 months preceding enrollment in the study. * diabetes mellitus requiring pharmacological control. * any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with the evaluation of the vaccine. * person deprived of freedom by an administrative or court order (having legal or medical guardian). * for women of childbearing potential, a positive urine pregnancy test, breast feeding, or not using a medically approved and reliable form of contraception (oral contraceptives or double barrier method) for the duration of the trial. * current use of alcohol or recreational drugs that may interfere with the subject's ability to comply with trial procedures. * thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination. * prior personal history of guillain-barré syndrome. \* subjects enrolled into this study will not be prohibited from donating blood for non-interventional studies.

Keywords: influenza